Results 31 to 40 of about 50 (49)
Some of the next articles are maybe not open access.
Dolutegravir: an exciting new kid on the block
Expert Opinion on Pharmacotherapy, 2014Dolutegravir is the first second-generation integrase inhibitor approved for the treatment of naïve as well as experienced HIV-infected individuals.Data from pharmacokinetics, efficacy, safety, tolerability and resistance are reviewed from in vitro studies, Phase II and III clinical trials published in PubMed (Dolutegravir; S/GSK1349572) or presented ...
Gary Whitlock, Jose Luis Blanco Arévalo
openaire +3 more sources
Dolutegravir dosing with rifampicin
The Lancet HIV, 2023Dario, Cattaneo, Cristina, Gervasoni
openaire +2 more sources
HIV Medicine
AbstractObjectivesThe availability of doravirine (DOR) allowed clinicians to prescribe a dolutegravir (DTG)‐based two‐drug regimen (2DR) in individuals not eligible to receive lamivudine (3TC) or rilpivirine (RPV). The aims of this study were to describe the durability of DTG + DOR compared with DTG/3TC and DTG/RPV and the rate of virological failure ...
Roberto Rossotti +10 more
openaire +2 more sources
AbstractObjectivesThe availability of doravirine (DOR) allowed clinicians to prescribe a dolutegravir (DTG)‐based two‐drug regimen (2DR) in individuals not eligible to receive lamivudine (3TC) or rilpivirine (RPV). The aims of this study were to describe the durability of DTG + DOR compared with DTG/3TC and DTG/RPV and the rate of virological failure ...
Roberto Rossotti +10 more
openaire +2 more sources
Synfacts, 2019 Dolutegravir–rilpivirine for virological suppression
The Lancet HIV, 2019Anton Pozniak +2 more
openaire +3 more sources
Rapid initiation of dolutegravir for adults in Botswana
The Lancet HIV, 2020Elizabeth D. Lowenthal +2 more
openaire +3 more sources